C-Reactive Protein Overexpression Exacerbates Pressure Overload–Induced Cardiac Remodeling Through Enhanced Inflammatory Response

Serum C-reactive protein (CRP) elevation predicts the development of heart failure in patients with hypertension. CRP activates macrophages and enhances oxidative stress. We hypothesize that CRP itself has a pathogenic role in the development of pressure overload–induced cardiac remodeling. Transgenic mice with human CRP overexpression (CRPtg) and nontransgenic littermates (CON) were subjected to transverse aortic constriction (TAC/CRPtg and TAC/CON) or sham operation (Sham/CRPtg and Sham/CON). One week after operation, in TAC/CRPtg, myocardial mRNA levels of interleukin (IL)-6, CD68, glutathione peroxidase-3 (GPx3), 47-kDa &agr;-subunit of nicotinamide adenine dinucleotide phosphate oxidase (p47phox), and collagen-I, the number of infiltrating Mac-2–positive macrophages, nuclear localization of phosphorylated NF-&kgr;B/p65 (p-p65) in cardiomyocytes, nuclear NF-&kgr;B-DNA-binding activity, and reactive oxygen species (ROS) content were increased compared to those in TAC/CON. Cardiac fibrosis was more prominent in TAC/CRPtg compared to TAC/CON. Four weeks after operation, heart and lung weights, cardiomyocyte cross-sectional area, and the extent of cardiac fibrosis were greater in TAC/CON than in Sham/CON, and these differences were further augmented in TAC/CRPtg compared to TAC/CON. Left ventricular (LV) fractional shortening was less and LV end-diastolic pressure was higher in TAC/CRPtg than in TAC/CON. Myocardial mRNA levels of angiotensin type 1 receptor, atrial natriuretic factor, IL-6, GPx3, p47phox, collagen-I, and transforming growth factor (TGF)-&bgr;1, the protein level of TGF-&bgr;1, and the numbers of Mac-2–positive macrophages and p-p65–positive cells were higher in TAC/CRPtg than in TAC/CON. In conclusion, CRP itself may have a pathogenic role in the development of pressure overload–induced cardiac remodeling, possibly through enhanced inflammation and oxidative stress.

[1]  S. Ogawa,et al.  Increased C-reactive protein expression exacerbates left ventricular dysfunction and remodeling after myocardial infarction. , 2010, American journal of physiology. Heart and circulatory physiology.

[2]  C. Lau,et al.  C-Reactive Protein Promotes Cardiac Fibrosis and Inflammation in Angiotensin II-Induced Hypertensive Cardiac Disease , 2010, Hypertension.

[3]  V. Hombach,et al.  Myocardial inflammation and non-ischaemic heart failure: is there a role for C-reactive protein? , 2009, Basic Research in Cardiology.

[4]  A. Ferreira,et al.  Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review. , 2009, Journal of cardiac failure.

[5]  W. Harris,et al.  Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. , 2009, Cardiovascular research.

[6]  N. Frangogiannis,et al.  Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload , 2009, Histochemistry and Cell Biology.

[7]  Gissi-Hf Investigators.  Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[8]  Y. Devaux,et al.  C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor α, on human monocytes , 2008, Thrombosis and Haemostasis.

[9]  S. Oparil,et al.  Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc gamma RI)-dependent. , 2008, The American journal of pathology.

[10]  L. Tavazzi,et al.  ect of n-3 polyunsaturated fatty acids in patients with chronic heart failure ( the GISSI-HF trial ) : a randomised , double-blind , placebo-controlled trial , 1980 .

[11]  E. Edelman,et al.  Transgenic expression of human C-reactive protein suppresses endothelial nitric oxide synthase expression and bioactivity after vascular injury. , 2007, American journal of physiology. Heart and circulatory physiology.

[12]  A. Hofman,et al.  C-reactive protein and risk of heart failure. The Rotterdam Study. , 2006, American heart journal.

[13]  B. DeGeorge,et al.  Cardioprotection afforded by NF-κB ablation is associated with activation of Akt in mice overexpressing TNF-α , 2006 .

[14]  B. DeGeorge,et al.  Cardioprotection afforded by NF-kappaB ablation is associated with activation of Akt in mice overexpressing TNF-alpha. , 2006, American journal of physiology. Heart and circulatory physiology.

[15]  U. Singh,et al.  C-Reactive Protein Decreases Tissue Plasminogen Activator Activity in Human Aortic Endothelial Cells: Evidence that C-Reactive Protein Is a Procoagulant , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[16]  J. Cohn,et al.  C-Reactive Protein in Heart Failure: Prognostic Value and the Effect of Valsartan , 2005, Circulation.

[17]  S. Ball,et al.  Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. , 2004, Cardiovascular research.

[18]  Lan Li,et al.  C-Reactive Protein Accelerates the Progression of Atherosclerosis in Apolipoprotein E–Deficient Mice , 2004, Circulation.

[19]  S. Ogawa,et al.  Association between serum C-reactive protein elevation and left ventricular thrombus formation after first anterior myocardial infarction. , 2004, Chest.

[20]  E. Olson,et al.  Cardiac hypertrophy: the good, the bad, and the ugly. , 2003, Annual review of physiology.

[21]  E. Edelman,et al.  Increased Thrombosis After Arterial Injury in Human C-Reactive Protein–Transgenic Mice , 2003, Circulation.

[22]  S. Verma,et al.  C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth Muscle , 2003, Circulation.

[23]  T. Imaizumi,et al.  Roles of Intercellular Adhesion Molecule-1 in Hypertensive Cardiac Remodeling , 2003, Hypertension.

[24]  Ren-Ke Li,et al.  A Self-Fulfilling Prophecy: C-Reactive Protein Attenuates Nitric Oxide Production and Inhibits Angiogenesis , 2002, Circulation.

[25]  A. Szalai,et al.  Varied biologic functions of c-reactive protein , 2002, Immunologic research.

[26]  C. Mold,et al.  C-Reactive Protein Binding to Murine Leukocytes Requires Fcγ Receptors1 , 2000, The Journal of Immunology.

[27]  C. Mold,et al.  C-reactive protein binding to murine leukocytes requires Fc gamma receptors. , 2000, Journal of immunology.

[28]  D. Bharadwaj,et al.  The Major Receptor for C-Reactive Protein on Leukocytes Is Fcγ Receptor II , 1999 .

[29]  S. Ogawa,et al.  Mechanical stretch activates the JAK/STAT pathway in rat cardiomyocytes. , 1999, Circulation research.

[30]  Janet M. Allen,et al.  A molecular switch changes the signalling pathway used by the FcγRI antibody receptor to mobilise calcium , 1998, Current Biology.

[31]  J Ross,et al.  Cardiac Muscle Cell Hypertrophy and Apoptosis Induced by Distinct Members of the p38 Mitogen-activated Protein Kinase Family* , 1998, The Journal of Biological Chemistry.

[32]  W. R. Taylor,et al.  Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. , 1997, Hypertension.

[33]  S. Ogawa,et al.  C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. , 1997, Circulation.

[34]  C. Long,et al.  Interleukin-1 beta induces cardiac myocyte growth but inhibits cardiac fibroblast proliferation in culture. , 1995, The Journal of clinical investigation.

[35]  R. Alexander.  Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. , 1995, Hypertension.

[36]  J. Ross,et al.  Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy , 1991, Proceedings of the National Academy of Sciences of the United States of America.